Affiliation:
1. Eli Lilly and Company Indianapolis Indiana USA
2. IQVIA Falls Church Virginia USA
3. Center for the Evaluation of Value and Risk in Health Institute for Clinical Research and Health Policy Studies Tufts Medical Center Boston Massachusetts USA
Abstract
AbstractINTRODUCTIONUnderstanding the prevalence of treatment‐eligible Alzheimer's disease (AD) is crucial for policy planning.METHODSWe used a comprehensive literature review and population cascade approach to estimate the number of amyloid‐positive, clinically diagnosed patients with mild cognitive impairment (MCI) or mild dementia due to AD in the United States.RESULTSAn estimated 666,646 individuals were identified as having MCI due to AD (range: 351,926–1,227,776) and 620,850 individuals as having mild dementia due to AD (range: 445,082–820,339). In a US population of 76 million individuals aged 60 or older in 2021, the estimates of MCI and mild dementia due to AD increased with age.CONCLUSIONSAs earlier diagnosis of AD and new disease‐modifying treatments become available, accurate population estimates are required to reduce uncertainty in the number of clinically diagnosed patients eligible for amyloid‐targeting therapies.
Subject
Psychiatry and Mental health,Neurology (clinical)
Reference32 articles.
1. Racial and Ethnic Differences in Knowledge About One's Dementia Status
2. Diagnosis of early Alzheimer's disease: clinical practice in 2021;Porsteinsson AP;J Prev Alzheimers Dis,2021
3. World Alzheimer Report 2021.GauthierS Rosa‐NetoP MoraisJA WebsterC.Journey through the diagnosis of dementia.Alzheimer's Disease International. Available at: (accessed May 16 2023)https://www.alzint.org/u/Abridged‐World‐Alzheimer‐Report‐2021_Jan2022.pdf
4. Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015–2060) in adults aged ≥65 years
5. Current understanding of Alzheimer’s disease diagnosis and treatment